Alteogen Announces Exclusive License Agreement with Tesaro, a Subsidiary of GSK, for the Development of a Subcutaneous Formulation of Dostarlimab Enabled by Hybrozyme™ Technology
DAEJEON, South Korea, Jan. 20, 2026 /PRNewswire/ — Alteogen Inc. (KOSDAQ: 196170) announced…
Misurata Free Zone Authority Signs $2.7 billion Landmark PPP to Transform Misurata Free Zone Port into a leading Mediterranean Gateway and Transhipment Hub